Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: An electrode sheet forming method includes: providing a first substrate having a defect and a second substrate having no defect; cutting the first substrate to divide the first substrate into a first portion having the effect and second portions having no defect; and connecting at least one second portion to the second substrate in the lengthwise direction of the second substrate to form an electrode sheet.

Abstract: An integrated circuit (IC) structure includes a semiconductor substrate, a first gate line, a second gate line, and a first auxiliary gate portion. The semiconductor substrate comprises a semiconductor fin. The semiconductor fin extends substantially along a first direction. The first gate line and the second gate line extend substantially along a second direction different form the first direction from a top view. The first auxiliary gate portion connects the first gate line to the second gate line from the top view.

Abstract: The present application provides an electrode assembly and a processing method and apparatus therefor, a battery cell, a battery, and a power consuming device. The electrode assembly includes: a cathode plate, an anode plate, and a separator, where the separator is configured to separate the cathode plate from the anode plate, a closed-pore portion is provided in part of the region of the separator, and the closed-pore portion is configured to block at least some ions de-intercalated from the cathode plate located on one side of the closed-pore portion from being intercalated into the anode plate located on the other side of the closed-pore portion. Heating the separator to form the closed-pore portion can reduce the occurrence of lithium precipitation.

Abstract: Provided are an electrode assembly, a battery cell, a battery, and a power consuming device. The electrode assembly includes: a cathode electrode plate, an anode electrode plate, and a separator, the separator being configured to isolate the cathode electrode plate from the anode electrode plate; and an electrolyte adsorption layer configured to be arranged along a surface of at least one of the cathode electrode plate, the anode electrode plate and the separator, wherein the electrolyte adsorption layer is provided with ion exchange channels, which are through holes provided in a thickness direction of the electrolyte adsorption layer. According to the technical solution described above, the electrolyte adsorption layer, which is arranged on the surface of at least one of the cathode electrode plate, the anode electrode plate and the separator, can adsorb and retain an electrolyte.

Abstract: An electrode assembly and a processing method and apparatus therefor, a battery cell, a battery, and a power consuming device are provided. The processing method includes: applying an adhesive on a preset part of a surface of a member to be coated, the adhesive forming a barrier layer, and the member to be coated including at least one of a cathode plate, a separator, and an anode plate; and winding the cathode plate, the anode plate, and the separator to form an electrode assembly. The barrier layer is located between the cathode active material layer and the anode active material layer adjacent to each other after the winding. The barrier layer blocks at least some ions de-intercalated from the cathode active material layer located on one side of the barrier layer from being intercalated into the anode active material layer located on the other side of the barrier layer.

Abstract: The present application provides an electrode assembly and a processing method and device therefor, a battery cell, a battery and a power consuming device. The electrode assembly comprises: a cathode plate, an anode plate and a separator. The cathode plate is bent M times to form M bent parts in a bent region, a first attachment region is formed on an inner surface of an Nth-bend part of the cathode plate, and a second attachment region is formed on an outer surface of the Nth-bend part; at least one part of an ion blocking layer is attached to the first attachment region, and the ion blocking layer is used for preventing ions deintercalated from the first attachment region from being intercalated into the anode plate adjacent to the first attachment region during charging; and at least one part of a reinforcing layer is attached to the second attachment region.

Abstract: Provided herein is technology relating to automated driving and particularly, but not exclusively, to a Vehicle Intelligent Unit (VIU) configured to provide vehicle operations and control for Connected Automated Vehicles (CAV) and, more particularly, to a VIU configured to connect with a Collaborative Automated Driving System (CADS) and manage and/or control information exchange between CAV and CADS and manage and/or control CAV lateral and longitudinal movements, including vehicle following, lane changing, and route guidance.

Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.

Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.

Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.

Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.

Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.

Abstract: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.

Abstract: Methods and systems for determining band structure characteristics of high-k dielectric films deposited over a substrate based on spectral response data are presented. High throughput spectrometers are utilized to quickly measure semiconductor wafers early in the manufacturing process. Optical dispersion metrics are determined based on the spectral data. Band structure characteristics such as band gap, band edge, and defects are determined based on optical dispersion metric values. In some embodiments a band structure characteristic is determined by curve fitting and interpolation of dispersion metric values. In some other embodiments, band structure characteristics are determined by regression of a selected dispersion model. In some examples, band structure characteristics indicative of band broadening of high-k dielectric films are also determined. The electrical performance of finished wafers is estimated based on the band structure characteristics identified early in the manufacturing process.